---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276022"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:29:22.518465+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics reports Q3 net loss of $2.1M; IND accepted for COYA 302 in ALS

## Summary
- Net loss of $2.1M for Q3 2025 improved from $4.0M loss in Q3 2024; cash and equivalents at $28.1M.
- FDA accepted IND for COYA 302 in ALS; ALSTARS Phase 2 trial launched with up to 25 sites.
- Closed $23.0M upsized public offering; cash runway extended into second half of 2027.
- Received $4.2M milestone from Dr. Reddy's for IND approval; additional $4.2M due on first dosing.

## SEC filing metadata
- accession: 0001193125-25-276022
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312525276022/0001193125-25-276022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312525276022/coya-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276022
- JSON: https://secwatch.observer/filing/0001193125-25-276022.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.